Decode Age raises Rs 14.5 crore to advance longevity science and gut microbiome research

Decode Age, a longevity science organisation focused on ageing biology, biomarker research and gut microbiome science, has raised Rs 14.48 crore in a pre-Series A funding round led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India Limited.

Founded in 2021, Decode Age has built a longevity research platform spanning multi-omics testing, biomarker discovery and precision-based interventions. Central to this platform is whole genome gut microbiome analysis systems, which offers high-resolution insights into microbial diversity and its role in immunity, metabolism and ageing pathways.

Decode Age said its laboratory workflows prioritise precision and reproducibility, supporting researchers, clinicians and individuals seeking deeper biological understanding and practical tools for healthy ageing. These insights are being applied to develop research-driven supplements and longevity solutions informed by ageing biology and microbiome data.

The startup will use the fresh capital to expand biomarker discovery programmes, advance its multi-omics and microbiome research pipeline, and strengthen scientific and analytical infrastructure.

It also plans to invest in formulation research aligned with key hallmarks of ageing, including cellular energy, metabolic balance, inflammatory pathways and cognitive resilience, while deepening collaboration across the longevity ecosystem.

“This investment marks an important step forward in our mission to bring scientific precision to the way people understand their biology,” said Parth Amin, CEO and co-founder of Decode Age.

“The support from Dr Chigurupati strengthens our ability to advance ageing and gut microbiome research, expand our biomarker programmes and build the scientific infrastructure that drives our work. We are grateful for his belief in our vision and remain committed to translating rigorous science into insights that help individuals make informed decisions about their long-term health.”

Dr Chigurupati said Decode Age is working in a field that could reshape how health, disease and ageing are understood.

“Decode Age is advancing an area of science that will redefine how we think about health, disease and ageing. Their capabilities in gut microbiome research and ageing biology are rigorous and forward-looking, offering individuals and clinicians biological insights that were previously inaccessible. This investment reflects my confidence in their scientific vision and the long-term impact they aim to create,” he said.

The startup is also building a scientific, clinical and product team to take its work to global markets. It aims to position India as a leader in microbiome science and healthy ageing research, while developing solutions that meet international standards of scientific rigour, quality and translational value.